MacroGenics Closes $30.5M Series B VC Round

MacroGenics, a Rockville, Md.-based firm that develops therapeutic antibodies for use in the treatment of various cancers and inflammatory diseases, has collected $30.5 million in a Series B round of private-equity financing, the company said last week.

MacroGenics lists Institute for Systems Biology co-founders Lee Hood, Alan Aderem, and Ruedi Aebersold among its founders, as well as Jeffrey Ravetch from Rockefeller University.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.